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Abstract Principles of follow-up management in 
patients treated for head and neck tumors are not very 
strictly defined, and practice varies between countries, 
centers, and specialists. Details of follow-up procedures, 
including timing of outpatient visits and diagnostic 
imaging, are specific for tumor types and localizations 
but also depend on treatment modalities used, availabil-
ity of diagnostic procedures, and socioeconomic factors. 
The authors describe general principles of follow-up in 
head and neck cancer patients. Clinical observation 
and laboratory and imaging studies in patients who had 
received radical treatment should focus on early identi-
fication of recurrent or second primary tumors to allow 
for a salvage radical therapy. In patients who initially had 
received a palliative care, the follow-up should focus on 
proper management of symptoms.
Keywords Oncological follow-up · Head and neck can-
cer · Recurrence · Metastases · Second primary tumor
Introduction
Management of head and neck cancer (HNC) is a seri-
ous challenge worldwide. In 2012, ~ 700,000 persons have 
been diagnosed and more than 370,000 died of HNC [1]. 
Standard radical therapy in early-stage HNC is surgery 
and/or radiotherapy (RT). Up to two-third of patients 
present with an advanced HNC, and surgical resection 
with adjuvant RT or radiochemotherapy (RTCT), RTCT 
alone, or RT with cetuximab are used. Overall prognosis 
is still unsatisfactory.
During 5-year follow-up, locoregional recurrence 
occurs in 25–50 % of patients with advanced cancer [2, 3]. 
Second primary cancers occur in 3–5 % of cases per year 
[4]. Salvage surgery, RT retreatment, chemotherapy (CT), 
and combined radical treatment can be implemented 
more frequently, and results are better if an early diag-
nosis of recurrence or of new cancer is made; however, 
it is possible in only up to 20 % of patients, and only 5 % 
with recurrence survive 5 years or more. In the majority 
of cases, only a palliative CT or supportive care is indi-
cated [2, 5, 6].
Another goal of follow-up care is detection and man-
agement of late complications that occur in 10–80 % 
of patients who underwent treatment for HNC [7–10]. 
Comorbidities are frequent in this group and require 
coordinated management. Dental care; psychological, 
emotional, and social support; and elimination of expo-
sure to risk factors that contributed to primary cancer 
are also important. Proper care for all those aspects by 
an interdisciplinary team has been shown to prolong sur-
vival and its quality [10, 11].
It is advisable to continue follow-up by the team that 
was involved in oncological management of the patient, 
with help from other specialists and professionals car-
ing for oncological patients [12]. Professionals not famil-
iar with problems of such patients might be reluctant to 
care for them, and it may result in a suboptimal care or in 
unnecessary procedures.
There is no commonly accepted standard of follow-up 
care in patients treated for HNC, and evidence support-
ing every aspect of this care is weak. Efficacy and cost-
effectiveness of different schedules, laboratory tests, and 
diagnostic imaging have not been established. Reviews 
show very large variability of existing practice [13–15]. 
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In this short paper, based on nonsystematic review, we 
present only the most frequently recommended proce-
dures. Due to complexity of HNC management and lack 
of strong evidence supporting recommended follow-up 
procedures, it is necessary to adapt these recommenda-
tions to individual situation of each patient.
Detection of locoregional recurrence, distant 
metastases, and second primary tumors
How frequent should be follow-up outpatient visits?
Published guidelines indicate that check-up visits in an 
oncology outpatient service should take place every 1–2 
months during the first 6 months after completion of 
treatment, every 2–3 months in the next 6 months, every 
3–4 months during second year, and every 6 months dur-
ing years 3–5 [12, 13, 16]. The visit 3 months after treat-
ment is particularly important because at this time, the 
baseline result of treatment should be established [17]. 
Besides detailed clinical assessment, a baseline imaging 
study is also advisable for all patients in whom direct or 
endoscopic visualization and palpation are not reliable 
or insufficient. If a complete response or radical resec-
tion has not been achieved, available options of radical 
retreatment have to be considered. If the disease persists 
and there are no radical treatment options, the follow-
up should continue according to principles described 
later in the text for patients who received a palliative 
treatment.
For a long time, the 5-year active oncological follow-up 
had been considered sufficient. However, HNC patients 
run 3–5 % yearly risk of second primary cancer through-
out their life, particularly if exposure to carcinogens con-
tinues. After 5 years, follow-up visit is advised every year 
[16], but effectiveness of this approach is not clear [18].
Which laboratory tests and diagnostic imaging are 
indicated?
Each follow-up visit should include careful history tak-
ing because presence of symptoms has been shown to 
indicate higher risk of recurrence [5, 18]. Detailed sys-
temic and site-specific examination is mandatory. With 
improved availability, an endoscopic examination has 
become a routine part of clinical assessment. Recorded 
endoscopic images can facilitate detection of a recur-
rence or a new tumor.
In localizations poorly accessible or not accessible to 
direct or endoscopic vision and/or palpation, diagnostic 
imaging is an indispensable part of follow-up.
Diagnostic imaging
CT scanning or MRI or both are indicated at the outset 
of observation. Afterward, these examinations are indi-
cated in symptomatic patients, but should not be advised 
as a routine. Imaging might be indicated when clinical 
assessment is not reliable [12, 16].
Ultrasound imaging of the neck is an easily available 
and inexpensive option in follow-up of regional lymph 
nodes. When coupled with fine-needle biopsy. it has high 
sensitivity and specificity, and can be used to improve 
accuracy of clinical neck examination [13].
Role of diagnostic imaging in detection of systemic 
spread is not clear. Traditional advice was to perform 
chest X-rays every year, but its sensitivity is low [13, 17]. 
In patients with high risk of second primary cancer (usu-
ally due to continuing smoking), yearly low-dose CT 
scan of the chest would be advisable [16]. Imaging of 
other organs/regions is advised only when indicated by 
symptoms.
Functional imaging
Availability and use of positron emission tomography 
(PET) do increase, and new modalities of imaging are 
introduced. Usefulness and effectiveness of these meth-
ods in routine follow-up are under investigation [19]. At 
present, PET scanning is not recommended in routine 
follow-up of patients treated for HNC, mainly due to 
relatively high rate of nonspecific, falsely positive results. 
PET is useful as a second-line diagnostic procedure in 
patients suspected of recurrent or second primary tumor 
when other diagnostic imaging procedures and biopsy 
are insufficient to confirm or rule out the cancer [17]. It is 
also increasingly used in staging of patients who are con-
sidered candidates for major salvage surgery procedures 
and in assessment of treatment results.
Laboratory tests
In HNC, there are no tumor cell markers that can be 
monitored during follow-up and used as an early indi-
cator of recurrence [12]. Use of routine laboratory tests 
should be adapted to the treatment the patient had 
received and its toxicity. One specific indication is mon-
itoring of thyroid function if the gland was included in 
irradiated field. Hypothyroidism occurs in up to 40 % of 
those patients, and TSH assessment every 6–12 months 
is advised [13, 16]. Approximately 15–30 % of RT/RTCT 
patients have nutritional problems that require monitor-
ing of liver function, protein level, and other nutritional 
parameters for as long as these problems persist [16, 20].
Biopsy
As mentioned earlier in the text, early diagnosis of recur-
rence has a positive impact on prognosis. Taking this into 
account, an active approach even to apparently “benign” 
symptoms and lesions is advisable. During follow-up, 
a standard initial attempt to histologically verify tissue 
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Sequels of surgical resection, such as deformities of 
face, impaired chewing and swallowing, speech distur-
bances, and stricture of the pharynx require constant 
attention during follow-up. Initially, oncological aspects 
take precedence over other concerns, but as risk of recur-
rence diminishes with time, sequels of therapy become 
increasingly important. An interdisciplinary team famil-
iar with management of oncological patient is necessary 
to assure proper management of these complex problems.
Radiochemotherapy
In HNC, cumulative doses of chemotherapeutics usu-
ally are not very high, but combined risk of early and late 
complications in patients receiving RTCT is significant 
[10]. Hematologic complications are the most frequent 
during treatment and occur in 37 % of cases, while the 
most frequent late complication in this group was dys-
function of pharynx/esophagus in 7 % [24]. Patients 
with adverse reactions due to CT should undergo regu-
lar laboratory tests. Management of CT complications is 
symptomatic.
Patients with HNC frequently have dysphagia, and it has 
major impact on quality of life. It is present before treat-
ment in at least 10 % of patients, during treatment and in 
early follow-up period in 80 % or more, and then gradually 
improves. Underreporting by patients is common [25–27]. 
It is important to actively check for dysphagia symptoms 
using standardized assessment tools. Loss of weight might 
indicate problems in swallowing. Xerostomia is a frequent 
contributing factor. Up to several percent of patients after 
RT/RTCT to the neck develop esophageal stricture that 
causes severe dysphagia and requires mechanical dilation 
or other surgical management.
Follow-up after palliative care
In patients who received only palliative care, the man-
agement during follow-up should concentrate on the 
quality of life. When no new symptoms appear, follow-
up visits can be reduced to a single visit 1–2 months after 
treatment completion. Diagnostic imaging is indicated 
only to guide palliative symptomatic procedures, par-
ticularly management of pain and maintenance of the 
airway. Follow-up of this group of patients should be 
coordinated by palliative care team.
Prevention of second primary tumors
Risk of second primary tumor can be reduced by elimina-
tion or reduction of exposure to carcinogens [28]. A con-
sultation and support from specialists in management 
of dependence should be advised. There are no specific 
medicines or supplements that have been proven to 
reduce risk of a new cancer or of the recurrence. Patients 
should be advised to maintain normal body weight, to 
suspected of persistent/recurrent/new cancer is the fine-
needle biopsy. Its accuracy can be enhanced by ultra-
sonographic or CT guidance. Positive results confirm 
recurrence, but negative/nondiagnostic results are of a 
limited value. If the lesion progresses, an incision biopsy 
should be done. For superficial lesions, a punch or inci-
sion biopsy under local anesthesia is recommended to 
provide definitive histopathological diagnosis.
Monitoring and management of treatment 
sequels, toxicity, and complications
Early and late undesirable effects appear after all types of 
oncological management and affect 10–90 % of patients 
[10]. Recently, there have been a growing number of 
patients treated with RTCT who run cumulative risk of 
complications. Complications and sequels of surgical 
resection usually occur early in postoperative period and 
tend to improve with time, while tissue damage due to RT 
and CT may be progressive and irreversible [21].
Radiotherapy
Early complications of RT include mainly acute muco-
sal reaction with dysphagia, pain, and xerostomia. Cur-
rently, skin reactions are less frequent due to progress in 
radiation technology. Intensity of early complications is 
dependent on fractionation scheme. Addition of CT very 
significantly increases frequency of early complications, 
but with exception of xerostomia, they tend to disappear 
within a few months after treatment.
Severe late complications of radical RT occur in 
10–15 % of patients [22]. Detection of late radiation toxic-
ity is based on detailed search for symptoms and signs. 
The most frequent are xerostomia and mucosal reac-
tions leading to difficulty in swallowing and significant 
deterioration of life quality [21]. Necrosis of the bone or 
cartilage occurs in 5–8 % of patients [10]. Tissue necrosis 
usually requires surgical treatment. Conservative symp-
tomatic treatment and physical methods are indicated to 
alleviate symptoms.
Surgery
Radical resection of an early HNC has low frequency of 
complications. However, majority of surgically treated 
patients have an advanced cancer and undergo complex, 
extensive surgical procedures. During early follow-up, 
particular attention should be paid to signs and symp-
toms of surgical site infection, as majority of these infec-
tions become apparent after discharge from hospital 
[23]. Early rehabilitation is advised to prevent shoulder, 
temporomandibular joint, speech, and swallowing dys-
function. Scarring, fibrosis, and contractures require 
early detection, physiotherapy, rehabilitation, and addi-
tional surgical interventions.
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pursue physical activity, and to eat regularly with partic-
ular attention to fruits, vegetables, and grain foods [29].
It is important to stress that published recommenda-
tions on timing of visits and investigations to be carried 
out are mostly based on expert opinion and observational 
or retrospective studies and reflect institutional practice. 
In comparison with NCCN guidelines [16], the recom-
mendations in this paper are more detailed and include 
some additional procedures, like ultrasonography imag-
ing with fine-needle biopsy in the evaluation of neck 
lymph nodes. The NCCN guidelines include an advice 
on dental evaluation in patients treated for oral cavity 
tumors and after RT involving oral cavity. We included 
this important part of follow-up care among psycho-
logical, emotional, and social support and elimination of 
exposure to risk factors to indicate the need for a com-
prehensive, interdisciplinary care. NCCN also included 
an option to monitor EBV status in nasopharyngeal can-
cer patients. In our paper, we do not include site-specific 
advice, but it is stressed that in view of insufficient evi-
dence and large variation in published practices, it is 
necessary to consider the situation of each patient on an 
individual basis.
Summary
Standard follow-up of patients treated for HNC is based 
on regular follow-up visits, with frequency decreasing in 
consecutive years. Imaging with CT and/or MRI is indi-
cated to establish treatment results and baseline stage for 
reference during observations. Ultrasonography of the 
neck is useful in assessment of regional lymph nodes. The 
most important goal of observation is an early diagno-
sis of recurrence or second primary tumors that under-
take salvage therapy and improves prognosis. Patients 
treated for HNC present with wide range of anatomical, 
functional, and emotional problems for which follow-
up management by a multidisciplinary team should be 
available.
Take-home message 
The main goal of patient observation during follow-up 
after treatment for a head and neck cancer is an early 
detection of recurrence or of second primary tumor. 
Observation and management during follow-up should 
be carried out by a multidisciplinary oncological team.
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